

U.S.S.N. 09/815,981
de Jong *et al.*
ELECTION AND PRELIMINARY AMENDMENT

Claims 1-16 and 30 are pending in this application. Claim 9 as filed had a typographical error; instead depending from claim 6 as intended and as is logical, claim 9 recited "166." In a Preliminary Amendment, it as incorrectly amended to depend from claim 23. The amendment herein restores the correct dependency. Upon entry of the amendment, claims 9 and 10 properly belong in group I. Accordingly, claims 9 and 10 are retained for examination on the merits.

Claims 17-29, 31 and 32 are cancelled. These claims will be prosecuted in co-pending U.S. application Serial No. 10/086,745.

Pursuant to 37 C.F.R. §1.121, a marked-up version of the amended claim is attached.

* * *

In view of the above amendments and remarks, examination and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24601-416B
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@HEWM.com



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: de Jong *et al.*

Serial No.: 09/815,981

Confirmation No.: 7622

Filed: March 22, 2001

For: METHODS FOR DELIVERING NUCLEIC
ACID MOLECULES INTO CELLS AND
ASSESSMENT THEREOF

Art Unit: 1636

Examiner: Sullivan, D.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"


"Express Mail" Mailing Label Number

EV175673604US

Date of Deposit October 17, 2002

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal "Express Mail Post Office to Addressee"
Service under 37 C.F.R. §1.10 on the date
indicated above and addressed to:

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Michael Lough

MARKED-UP CLAIM PURSUANT TO 37 C.F.R. § 1.121

9. (Twice Amended) The method of claim [23] 6, wherein step (a)
comprises contacting the nucleic acid molecule with a delivery agent that
comprises a cationic compound.

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900